CBCT-guided markerless stereotactic radiotherapy for kidney cancer
Official title: Organ Sparing Marker-less CBCT-guided Stereotactic Adaptive Radiotherapy for Primary Non-metastasized Renal Tumors
Run by Erasmus Medical Center · NCT07402109 · Data updated 2026-11-12
This project tests whether using CBCT imaging with breath-hold or surface-guided gating can deliver markerless SBRT more precisely for adults with non-metastatic kidney cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Erasmus Medical Center Academic / other |
| Locations | 1 site (Rotterdam, South Holland) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | January 1, 2030 |
| Study ends | January 1, 2030 |
| Registry record updated | April 8, 2026 |
| Trial ID | NCT07402109 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with histologically proven or imaging-suspected non-metastatic renal cell carcinoma who are eligible for SBRT and can give informed consent are the intended participants.
✕Probably not a fit
Patients with metastatic disease, prior high-dose radiotherapy to the kidney region, or those unable to cooperate with breath-hold or surface-guidance procedures are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Forty patients with non-metastatic renal cell carcinoma will receive stereotactic body radiotherapy (SBRT) at a single center. The first 15 patients will have extra breath-hold cone-beam CT scans during treatment to measure how much the kidney and tumor move between and during fractions and to see if surface guidance can act as a reliable stand-in for target position. Data from that first cohort will be used to develop a motion-management approach, after which 25 additional patients will be treated using the new technique (breath-hold or gated delivery combined with surface guidance) without implanted markers. The protocol includes the extra imaging dose needed to obtain the CBCT scans and aims to minimize planning margins by achieving reproducible target positioning.
Why it matters
Potential benefit: If successful, the approach could reduce radiation margins around the kidney tumor and lower unintended dose to normal kidney tissue, potentially reducing side effects while maintaining local control.
How similar studies have gone: SBRT has shown promising local control for renal cell carcinoma and surface-guided motion management has worked well in other tumor sites, but markerless CBCT-guided gating specifically for kidney tumors is a relatively novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with histologically proven non-metastastic RCC or high suspicion of RCC based on imaging without histological evidence * No metastatic lesions * Patients must be 18 years or older * Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician. Written informed consent Exclusion Criteria: * Previous high-dose radiotherapy in the region of the kidney
Where it's running
-
Erasmus MC
Rotterdam, South Holland, Netherlands Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Nectin-4 PET/CT imaging to differentiate renal tumors
This study tests a new PET tracer, 18F-N230A, to see if it helps distinguish renal cell carcinoma from renal pelvic urothelial carcinoma in adults.
-
Weight-loss programs to slow kidney cancer progression in small renal masses on active surveillance
This study tests two weight-loss approaches, daily calorie restriction and 5:2 intermittent fasting, to see if they help people with small kidney tumors on active surveillance lose weight and potentially slow cancer progression.
-
Predicting Toripalimab Response in High-Risk Recurrent Renal Cell Carcinoma using MRD
This study tests whether measuring minimal residual disease after surgery can predict which high-risk RCC patients will benefit from adjuvant Toripalimab.
-
Safety and tolerability test of anti-CD70 T-cell therapy in advanced RCC
This study tests a CD70-targeted CAR-T cell therapy in adults with advanced or metastatic renal cell carcinoma to see if it is safe and tolerable and to identify a usable dose for future studies.
-
VMD-102 in liver cancer and other solid tumors
This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.
-
Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance
This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.